secwatch / observer
8-K filed September 12, 2025, 7:59 PM ET ticker BNTC CIK 0001808898
other material confidence high sentiment negative materiality 0.70

Benitec Biopharma Inc. (BNTC): auditor change — Benitec restates Q2 and Q3 FY2025 financials for stock-comp understatement; prior filings unreliable

Benitec Biopharma Inc.

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Benitec Biopharma Inc. reported that prior financial statements should not be relied upon.

Action
non reliance
Auditor
Baker Tilly US, LLP
Exact text from the filing
onths ended December 31, 2024, contained in its Quarterly Report on Form 10-Q for the quarter ended December 31, 2024, originally filed with the SEC on February 14, 2025 (collectively, the “Prior Financial Statements”), should no longer be relied upon. The errors and corrective adjustments identified by the Company are non-cash in nature and resulted from the migration, in November 2023, of equity awards data to a new information recording system used to calculate the Company’s share-based compensation expense, which was incorrectly configured resulting in understatements of share-based compensation expense, which in turn led to understatements of additional paid-in capital, accumulated deficit, net loss and loss per share. The impact was immaterial to the Company’s previously issued financial statements prior to the quarter ended December 31, 2024, but the cumulative impact of the incor
View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR
accession 0000950170-25-114530
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.